Can­cer biotech In­ten­si­ty Ther­a­peu­tics looks to pull in $16M+ IPO

Can­cer biotech In­ten­si­ty Ther­a­peu­tics launched an IPO as it aims to ad­vance a ther­a­py be­ing test­ed in sar­co­ma and breast can­cer.

The Con­necti­cut biotech an­nounced Fri­day that it will sell 3.9 mil­lion shares of its com­mon stock at $5.00 a share while giv­ing its un­der­writ­ers an op­tion to ac­quire more shares. In­ten­si­ty is plan­ning to net around $16.2 mil­lion from the IPO.

Ac­cord­ing to the S-1 sub­mit­ted to the SEC on June 23, the pro­ceeds of the IPO will go to­ward work on the com­pa­ny’s pipeline and will give In­ten­si­ty enough cash to last through Sep­tem­ber 30, 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER